Taking on cancer with AI: Niven Narain, BERG Front Line Genomics

This week, New Orleans has played host to an enormous international gathering of cancer researchers at the American Association for Cancer Research Annual Meeting. At the meeting, FLG's own Katie Draper caught up with Niven Narain of Boston-Based biopharma company BERG to learn about cancer drug development, and explore how artificial intelligence can contribute to precision medicine. FLG: Tell us a bit about yourself and your role at BERG. NN: Sure, I'm Niven Narain, Founder and CEO of BERG, and as Founder much of my role involves bringing forth the vision of the technologies, and to put forward these products that are now in clinical trials for cancer, namely BPM31510. The vision is really to get these drugs to patients as quickly as possible, but importantly using a precision medicine approach so that we're not falling into a one-size-fits all.